HE4 positive expression rate was 82.14% in type I endometrial cancer and 87.84% in type II (P = 0.456); HE4 positive expression rates in endometrial adenocarcinoma, serous papillary carcinoma, clear cell carcinoma of the uterus, and other special pathological types were 91.84%, 71.43%, and 86.36%, respectively, and showed no significantly statistical difference between the groups (P > 0.05) (Figure 1, Table 2). This evidence concerns the gene WFDC2 and endometrial cancer.